LY 3009806 hits endpoint in Phase III study of Gastric Cancer

Topline results for the RAINBOW trial, a global Phase III study of LY 3009806 (ramucirumab), from Eli Lilly, in combination with paclitaxel in patients with advanced Gastric Cancer, show the drug has met its primary endpoint of improved overall survival and a secondary endpoint of improved progression-free survival. The global, randomized, double-blind RAINBOW trial compared ramucirumab and paclitaxel to placebo and paclitaxel in patients with locally advanced, unresectable or metastatic Gastric Cancer that was refractory to or progressive after initial chemotherapy.

The most common adverse events occurring on the ramucirumab-plus-paclitaxel arm included neutropenia, leukopenia, hypertension, fatigue/asthenia and abdominal pain. Lilly plans to present data from the RAINBOW trial at an upcoming scientific meeting and intends to submit an application for ramucirumab in combination with paclitaxel to regulatory authorities.